Search

Your search keyword '"Ilaria Spalliera"' showing total 2 results
Start Over Author "Ilaria Spalliera" Topic 030212 general & internal medicine
2 results on '"Ilaria Spalliera"'

1. Baseline T-lymphocyte subset absolute counts can predict both outcome and severity in {SARS}-{CoV}-2 infected patients: a single center study

Author

Francesco Buccisano, Daniela Fraboni, Elisabetta Teti, Andrea Di Lorenzo, Marco Iannetta, Massimo Andreoni, Vincenzo Malagnino, Angela Crea, Marta Zordan, Laura Campogiani, Raffaele Palmieri, Ilaria Spalliera, Pietro Vitale, Benedetta Rossi, Maria Teresa Voso, and Loredana Sarmati

Subjects
0301 basic medicine, CD4-Positive T-Lymphocytes, Male, medicine.medical_specialty, Science, Rome, CD8-Positive T-Lymphocytes, Single Center, Logistic regression, Predictive markers, Gastroenterology, Severity of Illness Index, Article, Settore MED/06, 03 medical and health sciences, 0302 clinical medicine, T-Lymphocyte Subsets, Internal medicine, Nasopharynx, Severity of illness, Medicine, Humans, 030212 general & internal medicine, Hospital Mortality, Lymphocyte Count, Aged, Retrospective Studies, Aged, 80 and over, Multidisciplinary, business.industry, Reverse Transcriptase Polymerase Chain Reaction, SARS-CoV-2, COVID-19, Retrospective cohort study, T lymphocyte, Middle Aged, Peripheral, 030104 developmental biology, Risk factors, Peripheral blood lymphocyte, Female, business, Infection, CD8
Abstract

The aim of this study was to evaluate the role of baseline lymphocyte subset counts in predicting the outcome and severity of COVID-19 patients. Hospitalized patients confirmed to be infected with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) were included and classified according to in-hospital mortality (survivors/nonsurvivors) and the maximal oxygen support/ventilation supply required (nonsevere/severe). Demographics, clinical and laboratory data, and peripheral blood lymphocyte subsets were retrospectively analyzed. Overall, 160 patients were retrospectively included in the study. T-lymphocyte subset (total CD3+, CD3+ CD4+, CD3+ CD8+, CD3+ CD4+ CD8+ double positive [DP] and CD3+ CD4− CD8− double negative [DN]) absolute counts were decreased in nonsurvivors and in patients with severe disease compared to survivors and nonsevere patients (p

Published
2021

2. Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab

Author

Doriana Landi, Marco Iannetta, Mirko Compagno, Pietro Vitale, Novella Cesta, Christof Stingone, Vincenzo Malagnino, Girolama Alessandra Marfia, Elisabetta Teti, Ilaria Spalliera, Andrea Di Lorenzo, Loredana Sarmati, Giuseppe De Simone, Benedetta Rossi, Lorenzo Ansaldo, Massimo Andreoni, and Carolina Gabri Nicoletti

Subjects
Male, Disease, 0302 clinical medicine, Monoclonal, Pandemic, Disease modifying therapies, Viral, 030212 general & internal medicine, Humanized, Clinical course, General Medicine, Middle Aged, Neurology, Female, Coronavirus Infections, medicine.drug, Adult, medicine.medical_specialty, Multiple Sclerosis, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Pneumonia, Viral, Clinical Neurology, Settore MED/26, Antibodies, Monoclonal, Humanized, Antibodies, Article, Betacoronavirus, Immunocompromised Host, 03 medical and health sciences, Disease severity, Internal medicine, DMD, medicine, Humans, Immunologic Factors, Pandemics, IL-6, business.industry, Multiple sclerosis, DMT, COVID-19, Pneumonia, MS, medicine.disease, Settore MED/17, respiratory tract diseases, Ocrelizumab, Neurology (clinical), business, 030217 neurology & neurosurgery
Abstract

Highlights • Ocrelizumab is not associated to increased severity in MS patients with COVID-19. • B-cell depleting treatment could impact on virus-specific antibody production. • B-cell depleting therapies can reduce IL-6 production, thus modulating inflammation., Background Recently SARS-CoV-2 has spread worldwide causing a pandemic. Little is known about disease severity in immunocompromised hosts and people receiving disease modifying therapies (DMTs). In the last decades DMTs have been widely employed, and ocrelizumab represents one of the newest therapies for the relapsing remitting and progressive forms of multiple sclerosis (MS). Objectives to describe SARS-CoV-2 related pneumonia in two MS patients under ocrelizumab treatment. Methods Case series. Results Patients showed a mild clinical course of SARS-CoV-2 related pneumonia without complications or sequelae. Conclusion Ocrelizumab treatment is not necessarily associated to increased severity in MS patients with SARS-CoV-2 infection.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results